Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Julie Plyler is a member of the firm’s corporate practice group and focuses on capital markets and securities transactions in the life sciences industry. She also represents companies in connection with financing transactions.
- Represented BioNTech SE in its initial public offering.
- Represented the underwriters in the initial public offering of Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.
- Represented the underwriters in a global offering of ordinary shares and ADSs of ERYTECH Pharma S.A., a France-based company developing therapies for rare forms of cancer and orphan diseases using a novel technology to encapsulate therapeutic drug substances inside red blood cells.
- Represented the underwriters in the initial public offering and follow-on offering of American Depositary Shares of Nightstar Therapeutics plc, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases.
- Represented the underwriters in the U.S. initial public offering and multiple follow-on offerings of ordinary shares of UroGen Pharma Ltd., an Israeli biopharmaceutical company focused on non-surgical treatments in uro-oncology.
- Represented MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, in multiple follow-on offerings and a registered direct offering of common stock.
- Advises public companies on Exchange Act periodic reporting, proxy statements, Section 16 reporting and securities compliance matters.
Pro Bono
- Provides legal services and advice to the Jackie Robinson Foundation, a national, not-for-profit organization committed to perpetuating the memory of Jackie Robinson by promoting civic engagement and humanitarian ideals as well as addressing the achievement gap in higher education, in connection with the development of the Jackie Robinson Museum.
- Provides ongoing legal services and advice to Village Health Works, a 501(c)(3) nonprofit organization focused on providing quality health care in rural Burundi.
February 25, 2019, Covington Alert
On February 19, 2019, the Securities and Exchange Commission (the “SEC”) proposed a new rule under the Securities Act of 1933 (the “Securities Act”) that would expand issuers’ ability to gauge potential investor interest in registered securities offerings.
January/February 2018, The Corporate Governance Advisor
Covington Advises SK Holdings in Acquisition of Significant Minority Interest in Eureka Midstream
October 27, 2017
NEW YORK—Covington represented SK Holdings Co., Ltd. in its acquisition of a significant minority interest in Eureka Midstream Holdings, LLC, a midstream energy company that owns and operates approximately 340 miles of gas gathering pipelines in Ohio and West Virginia. The transaction closed in early October 2017. SK Group is a top three conglomerate in South ...
September 26, 2017, Covington Alert
On September 21, 2017, the Securities and Exchange Commission (the “SEC”), as well as the SEC’s Division of Corporation Finance (the “Staff”), published new interpretive guidance to assist public companies in complying with the SEC’s pay ratio disclosure rule. The new guidance addresses many questions that have been raised regarding the rule, including how a ...